Ankylosing Spondylitis Therapeutics Market to Grow with a CAGR of 7.45% through 2030

Rising Prevalence of Ankylosing Spondylitis and Aging Population and Chronic Disease Burden are factors driving the Global Ankylosing Spondylitis Therapeutics Market in the forecast period 2026-2030

According to TechSci Research report, “Ankylosing Spondylitis Therapeutics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Ankylosing Spondylitis Therapeutics Market stood at USD 5.10 Billion in 2024 and is anticipated to grow with a CAGR of 7.45% in the forecast period, 2026-2030.

Ankylosing spondylitis (AS), a progressive autoimmune disorder that primarily targets the axial skeleton, continues to represent a significant clinical and economic challenge due to its chronic nature and impact on patient mobility and quality of life. Characterized by persistent inflammation of the spine and sacroiliac joints, AS leads to structural damage, functional impairment, and long-term disability in a growing global patient population. In response, the global AS therapeutics market is undergoing a rapid evolution, propelled by a combination of scientific innovation, demographic shifts, and rising disease recognition.

The increasing global prevalence of ankylosing spondylitis is a key catalyst for market expansion. As prevalence rates continue to rise across both developed and emerging markets, the unmet demand for advanced, sustained treatment options is creating significant opportunities for pharmaceutical companies, specialty care providers, and diagnostics firms.

Scientific progress in understanding the molecular and genetic mechanisms of AS has accelerated therapeutic innovation. The identification of novel biomarkers and pathogenic pathways, including the role of HLA-B27 and pro-inflammatory cytokines, is enabling the development of more targeted and disease-modifying treatments. These insights are not only de-risking drug development pipelines but also laying the groundwork for companion diagnostics and precision medicine approaches shifting the market from symptom control to mechanism-based intervention.

The adoption of biologic therapies particularly TNF-alpha inhibitors (e.g., adalimumab, infliximab) and IL-17 inhibitors (e.g., secukinumab, ixekizumab)—has transformed the therapeutic landscape for AS. These agents have demonstrated superior efficacy in controlling inflammation and preserving function, compared to conventional NSAIDs or DMARDs. As real-world data reinforces their long-term benefit-risk profiles, pharmaceutical companies are investing heavily in next-generation biologics, biosimilars, and oral small molecules targeting IL-23, JAK, and TYK2 pathways. This continued R&D momentum is translating into a robust late-stage pipeline and fueling product differentiation within the market.

Although AS often first presents in early adulthood, its chronic trajectory requires sustained medical management over decades. With global life expectancy rising and healthcare infrastructure improving in many regions, a growing population of aging AS patients is contributing to ongoing treatment demand. This trend is pushing stakeholders to develop therapies with improved tolerability and lower cumulative toxicity, tailored for long-term use among older adults with comorbidities. The aging demographic thus represents a stable, high-value segment within the broader AS therapeutics market.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Ankylosing Spondylitis Therapeutics Market”

The Global Ankylosing Spondylitis Therapeutics Market is segmented into Drug, End Use, regional distribution and company.

Based on End Use, The hospital segment is projected to experience rapid growth during the forecast period. Hospitals typically have specialized departments or units, such as rheumatology departments, that focus on treating autoimmune diseases like ankylosing spondylitis. Rheumatologists, who are experts in managing AS, are more commonly found in hospital settings. This specialization is crucial for providing the best care and treatment options for AS patients. Hospitals often have access to the latest and most advanced treatments for ankylosing spondylitis. This may include biologic therapies, which have shown efficacy in managing the condition. These therapies are often administered in a hospital setting, requiring close monitoring due to potential side effects. Ankylosing spondylitis can lead to physical limitations, and rehabilitation services such as physical therapy are often an integral part of the treatment plan. Hospitals typically offer comprehensive rehabilitation services, which can be essential for AS patients in improving their mobility and quality of life. The management of AS may require a multidisciplinary approach involving rheumatologists, physical therapists, orthopedic surgeons, and other specialists. Hospitals are well-suited to facilitate collaboration among these healthcare professionals to provide comprehensive care for AS patients. AS patients may experience complications or exacerbations of their condition that require emergency medical attention. Hospitals are equipped to handle such situations, ensuring timely and appropriate care in case of emergencies. Hospitals often engage in research and clinical trials related to ankylosing spondylitis. This research can lead to the development of new treatments and therapies, further solidifying their role in the AS market.

Based on region, The Asia Pacific region is experiencing rapid market growth. The Asia Pacific has active patient advocacy and support groups that raise awareness about AS, support research efforts, and provide resources for patients. These organizations can influence treatment options and market dynamics.

Major companies operating in Global Ankylosing Spondylitis Therapeutics Market are:

• AbbVie, Inc.
• Amgen, Inc.
• Pfizer, Inc.
• Novartis AG
• Eli Lilly and Company
• UCB, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc

Download Free Sample Report

Customers can also request 10% free customization in this report.

“The global ankylosing spondylitis market is poised for significant growth, driven by factors such as increasing prevalence, advances in medical research, the biologics revolution, an aging population, patient advocacy and awareness, and favorable reimbursement policies. These drivers are creating opportunities for pharmaceutical companies, healthcare providers, and other stakeholders to develop and deliver innovative treatments and solutions for AS patients. As research continues and new therapies emerge, the outlook for the global AS market remains promising in its efforts to improve the lives of those affected by this chronic autoimmune condition.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia), By End Use  (Hospitals, Clinics, Others), By Region & Competition, 2020-2030F”, has evaluated the future growth potential of Global Ankylosing Spondylitis Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Ankylosing Spondylitis Therapeutics Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com